Both Moderna and Pfizer-BioNTech manufacture the COVID vaccine in lower doses ... but they're not immune to the virus. "At ...

Driven by the early approval of its updated COVID-19 vaccine, BioNTech far exceeded analysts’ expectations in the third ...

Presented clinical data for multiple assets across modalities, including bispecific antibody candidate BNT327/PM8002 and mRNA cancer vaccine ...

Antiviral Immunoglobulin Market. The global antiviral immunoglobulin market was valued at USD 4.6 billion in 2022 and is ...

In August, the Food and Drug Administration authorized updated vaccines against COVID-19. Here's what to know about the three vaccines available in the U.S.

The 2024–2025 COVID-19 vaccines are recommended for everyone aged 6 months and older in the US to target the currently circulating SARS-CoV-2 strains, JN.1 and KP.2.

1-lineage omicron variants of the coronavirus, or SARS-CoV-2. The options include the mRNA vaccines from Pfizer/BioNTech and ...

Non-clinical data showed better response compared to the Omicron XBB.1.5-adapted vaccine. The Health Sciences Authority has ...

LANE COUNTY, Ore. -- An early morning shots-fired incident in Springfield has led to the arrest of two individuals after a coordinated, multi-agency pursuit through multiple towns, ending in Cottage ...

On Aug. 22, the Food and Drug Administration approved and authorized newer formulations of the two mRNA vaccines, from Pfizer/BioNTech and Moderna, for ages 6 months and up. About a week later ...